Last updated: 20 February 2024 at 4:31pm EST

Christian Vasquez Net Worth




The estimated Net Worth of Christian Vasquez is at least $333 Thousand dollars as of 19 December 2023. Mr Vasquez owns over 7,495 units of BioAtla stock worth over $207,030 and over the last 4 years he sold BCAB stock worth over $125,990.

Mr Vasquez BCAB stock SEC Form 4 insiders trading

Mr has made over 6 trades of the BioAtla stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 7,495 units of BCAB stock worth $15,290 on 19 December 2023.

The largest trade he's ever made was buying 50,000 units of BioAtla stock on 7 June 2022 worth over $151,000. On average, Mr trades about 2,505 units every 23 days since 2020. As of 19 December 2023 he still owns at least 115,659 units of BioAtla stock.

You can see the complete history of Mr Vasquez stock trades at the bottom of the page.





Mr. Christian Vasquez biography

Christian Vasquez is the VP of Fin., Corp. Controller & Sec. at BioAtla.



How old is Mr Vasquez?

Mr Vasquez is 46, he's been the VP of Fin. and Corp. Controller & Sec. of BioAtla since . There are 5 older and 1 younger executives at BioAtla. The oldest executive at BioAtla, Inc. is Richard A. Waldron, 67, who is the Chief Financial Officer.

What's Mr Vasquez's mailing address?

Christian's mailing address filed with the SEC is C/O BIOATLA, INC. 11085 TORREYANA ROAD, , SAN DIEGO, CA, 92121.

Insiders trading at BioAtla

Over the last 4 years, insiders at BioAtla have traded over $51,913,006 worth of BioAtla stock and bought 2,491,625 units worth $40,365,176 . The most active insiders traders include Guy Levy, Asset Management, Lp Chen B..., and Jay M Phd Short. On average, BioAtla executives and independent directors trade stock every 25 days with the average trade being worth of $157,753. The most recent stock trade was executed by Sylvia Mcbrinn on 26 December 2023, trading 4,000 units of BCAB stock currently worth $9,320.



What does BioAtla do?

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.



What does BioAtla's logo look like?

BioAtla, Inc. logo

Complete history of Mr Vasquez stock trades at BioAtla

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
19 Dec 2023 Christian Vasquez
See Remarks
Buy 7,495 $2.04 $15,290
19 Dec 2023
115,659
28 Mar 2023 Christian Vasquez
See Remarks
Buy 20,000 $2.40 $48,000
28 Mar 2023
102,709
7 Jun 2022 Christian Vasquez
See Remarks
Buy 50,000 $3.02 $151,000
7 Jun 2022
74,525
30 Nov 2021 Christian Vasquez
See Remarks
Sale 1,979 $23.48 $46,467
30 Nov 2021
25,259
29 Nov 2021 Christian Vasquez
See Remarks
Sale 642 $23.89 $15,337
29 Nov 2021
27,238
22 Nov 2021 Christian Vasquez
See Remarks
Sale 2,541 $25.26 $64,186
22 Nov 2021
27,880


BioAtla executives and stock owners

BioAtla executives and other stock owners filed with the SEC include: